Myriapod NGS Line

Myriapod NGS Line 2017-09-08T12:32:09+00:00

Complexity made easy

Key features:

  1. Easy to use: single tube multiplex PCR.
  2. Ready for diagnostics: CE IVD marked. Validated for the qualitative and quantitative evaluation of SNVs, indels and CNVs for both somatic and germline analysis.
  3. Minimum quantity of DNA needed: 10-25 ng of DNA per sample.
  4. Quality inside: Positive control with orthogonally validated genotype (Horizon Discovery) included in the kit.
  5. Data analysis: dedicated software and workstation for automated data analysis.

The kit includes all the necessary reagents for:

  • qualitative and quantitative evaluation of the input DNA by qPCR (for somatic analysis);
  • multiplex PCR for library preparation;
  • enrichment of the library through PCR.

Myriapod® NGS Data Analysis workstation and software: from NGS raw data to clinical results

The Diatech data analysis solution is made of an easy-to-use CE IVD software running on a bespoke workstation. The software allows local analysis of raw sequencing data and the calling of SNVs, indels and CNVs. Myriapod NGS data Analysis Key features:

  • Dedicated and complete solution for local data analysis: Myriapod NGS Analysis software and the dedicated Myriapod NGS workstation are an end-to-end solution for local analysis.
  • Flexibility: same data analysis solution for both Illumina® and Thermo Fisher Scientific® platforms.
  • “Variants database” dedicated to each application The software stores all the variants detected by each application; the user can re-classify any variant for internal use.
  • Monitor progress Once the analysis has started, the user can monitor its progress in an easy way.
  • Categorized results Variants are automatically binned into categories based on quality and realiability of the call.
  • Integrated IGV data visualizer All data can be viewed with the integrated IGV viewer, allowing to visually inspect the coverage of the interested regions. Report The software allows to select sequencing metrics and results and print them in a PDF file report or export them in .csv format.

Principle of the method: Myriapod® NGS BRCA1-2 panel CE IVD kit allows the detection of the variants of BRCA1-2 and PALB2 implicated in breast and ovary cancer.
Starting material: genomic DNA extracted from blood, fresh, frozen or formalin-fixed paraffin embedded (FFPE) tissue.
Intended use: CE IVD workflow from DNA to data analysis of BRCA1-2 and PALB2 whose alterations have been implicated in breast and ovary cancer.

Every described variant is displayed and compared with:

  • clinical databases (e.g. Clin-Var);
  • variant frequency in the population databases (e.g. 1000 Genomes);
  • predictive algorithms of the mutation effect on the encoded transcription or protein.

The CNV (Copy Variation Number) analysis is displayed for each gene (BRCA1, BRCA2 e PALB2); each analyzed exon is viewed as the variation from the gene normal copy number. “O” value means a normal number of copies, “1” means a duplication and “-1” means a deletion. “High” and “Low confident” identify the confidence in the result.

Principle of the method: Myriapod® NGS 56G Onco panel CE IVD kit allows the detection of the main variants of 56 genes whose alteration has been shown to be clinically relevant in different tumors.

Starting material: genomic DNA extracted from fresh or formalin-fixed paraffin embedded (FFPE) tissue.

Intended use: CE IVD workflow from DNA to data analysis of 56 genes whose alterations have been shown to be of clinical relevance in oncology.

Genes included in the panel:

Principle of the method: Myriapod® NGS BRCA1-2 panel CE IVD kit allows the detection of the variants of BRCA1-2 and PALB2 implicated in breast and ovary cancer.
Starting material: genomic DNA extracted from blood, fresh, frozen or formalin-fixed paraffin embedded (FFPE) tissue.
Intended use: CE IVD workflow from DNA to data analysis of BRCA1-2 and PALB2 whose alterations have been implicated in breast and ovary cancer.

Every described variant is displayed and compared with:

  • clinical databases (e.g. Clin-Var);
  • variant frequency in the population databases (e.g. 1000 Genomes);
  • predictive algorithms of the mutation effect on the encoded transcription or protein.

The CNV (Copy Variation Number) analysis is displayed for each gene (BRCA1, BRCA2 e PALB2); each analyzed exon is viewed as the variation from the gene normal copy number. “O” value means a normal number of copies, “1” means a duplication and “-1” means a deletion. “High” and “Low confident” identify the confidence in the result.

Principle of the method: Myriapod® NGS 56G Onco panel CE IVD kit allows the detection of the main variants of 56 genes whose alteration has been shown to be clinically relevant in different tumors.

Starting material: genomic DNA extracted from fresh or formalin-fixed paraffin embedded (FFPE) tissue.

Intended use: CE IVD workflow from DNA to data analysis of 56 genes whose alterations have been shown to be of clinical relevance in oncology.

Genes included in the panel:

Download the Myriapod NGS system brochure
Category

Sequencing

Validated tools
MiSeq System Illumina®
Ion PGM system Thermo Fisher®
Ion S5 system Thermo Fisher®
Request information

Please insert your email address below, we will contact you soon.

I consent to privacy